New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor plus aspirin was associated with similar rates of recurrent coronary revascularization, major adverse cardiac and cerebrovascular events (MACCE) and a lower risk of net adverse clinical events (NACE) compared with duel antiplatelet therapy (DAPT).
TWILIGHT trial reveals the impact of DAPT and ticagrelor monotherapy after percutaneous coronary intervention
- Thread starter Educator
- Start date